<DOC>
	<DOC>NCT00174187</DOC>
	<brief_summary>- To assess the effect of a long-term treatment by Genotonorm on linear growth in children with short stature receiving steroid therapy - To assess the effect of a long term treatment with Genotonorm on bone mineralisation - To assess the effect of a long term treatment with Genotonorm on body composition</brief_summary>
	<brief_title>Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy</brief_title>
	<detailed_description>This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.</detailed_description>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Children with juvenile arthritis or nephrotic syndrome Before or during puberty Diabetes Type 1 and 2 Endocrine disease, except well substituted hypothyroidism</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>